CUCihat Uzunkopru

Cihat Uzunkopru

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cihat Uzunkopru has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population

    by Meral Seferoğlu, Bilge Piri Çınar, Ülgen Yalaz Tekan, Fatma Avşar, Pınar Yiğit, Ali Özhan Sıvacı, Serkan Demir, Melih Tütüncü, Haluk Gümüş, Cihat Uzunköprü, et al.

    Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.


  • A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey

    by Serkan Demir, Melih Tutuncu, Cihat Uzunkopru, Haluk Gumus, Sedat Sen, Tuncay Gunduz, Ipek Gungor Dogan, Bilge Piri Cinar, Sila Usar Incirli, Mesude Tutuncu, et al.


  • A Rare Presentation of Spontaneous Intracranial Hypotension

    by Cihat Uzunköprü, Volkan Çakır, Şehnaz Arıcı, Yeşim Beckmann


  • Invasive Therapies in Multiple Sclerosis

    by Cihat Uzunkopru

    Multiple sclerosis is a progressive disease despite so many recent therapy agents. Many symptoms can be seen that can affect the quality of daily life, such as spasticity, urinary incontinence, sensory disturbances, and tremor. These complaints may be refractory to the medical treatments, and the invasive treatment methods may be the only option to improve the quality of life of the patient. Intrathecal baclofen pump therapy can effectively reduce the spasticity in a patient with an inadequate response to oral baclofen. On the other hand, deep brain stimulation significantly reduces tremor and can provide the patient to eat by his/her self. Sacral neuromodulation may be beneficial in a patient with a history of urge incontinence which doesn't respond to oral agents. Adequate pain control can be achieved with spinal cord stimulators when a patient is unresponsive to the neuropathic pain treatment. Common features of all these invasive therapies are that they are used in patients who do not respond to medical treatments, they have a small number of randomized controlled clinical trial, and almost all of them are incompatible with MRI devices. According to the latest researches, more randomized controlled clinical trials and MRI compatible devices have been produced in recent years. We wanted to discuss these treatment methods even they have not yet been used routinely. We think they would be beneficial in clinical practice after their deficiencies have been overcome.